On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes absolute intolerance of skin to sunlight, and Clinuvel’s novel drug SCENESSE® (afamelanotide), which has been trialed as a photoprotective in EPP. Clinuvel has subtitled the 'Check up' program and re-released for the broader EPP community.
All footage and soundtrack are copyright © Telezueri 2012.
'Check up' reports on rare disease EPP and SCENESSE® (afamelanotide)
28
Feb
2012
-
font size
decrease font size
increase font size
Tagged under
Clinuvel Blog Posts
The biennial Porphyrins & Porphyrias conference is the only international meeting of global key opinion leaders on the group of...
Read More
Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...
Read MoreWe've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...
Read MoreClinuvel Webcasts
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Clinuvel Spotlight
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an... Read more |
